Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

1.56
-0.0100-0.64%
Post-market: 1.52-0.0400-2.56%19:00 EDT
Volume:30.68K
Turnover:48.11K
Market Cap:3.49M
PE:-0.06
High:1.62
Open:1.55
Low:1.54
Close:1.57
52wk High:29.28
52wk Low:1.50
Shares:2.24M
Float Shares:2.05M
Volume Ratio:0.53
T/O Rate:1.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.47
PE(LYR):-0.02

Loading ...

HCW Biologics - Q1 2026 Financial Statements Should no Longer be Relied upon - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - Errors Constitute Material Misstatement of EPS - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - Error in Two-Class Method for EPS Calculation Identified - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics - EPS of $2.19 Per Share Overstated by $0.80 Per Share for Q1 2026 - SEC Filing

THOMSON REUTERS
·
Aug 15

HCW Biologics Says Q1 2026 Financials Cannot be Relied on Due to EPS Misstatement

Reuters
·
Aug 15

Top Brass Makes Bold Move on HCW Biologics Shares

TIPRANKS
·
Aug 01

HCW Biologics Director Scott T. Garrett Acquires 7,736 Common Shares for $19,995.56

Reuters
·
Aug 01

HCW Biologics Issues 400,000 Pre-funded Warrants in $1.6 Million Private Placement

Reuters
·
Jul 29

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

THOMSON REUTERS
·
Jul 29

HCW Biologics Seeks FDA Pre-ind Meeting for Hcw11-018b T-cell Engager Program

Reuters
·
Jul 23

HCW Biologics - Requests Type B Pre-ind Meeting with FDA for Hcw11-018b

THOMSON REUTERS
·
Jul 23

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-generation T-cell Engager Program on Track to Initiate Clinical Trials in First Half 2027

THOMSON REUTERS
·
Jul 23

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

GlobeNewswire
·
Jul 23

HCW Biologics Resolves Disputes, Clears Miramar Property Liens

TIPRANKS
·
Jul 01

HCW Biologics - Pays in Full Amounts Owed to Eirgenix Under Settlement Agreement on May 26, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics - to Report Settlement of $2.8 Mln Disputed Accounts Payable in Q2 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics - B&I Contractors Files Voluntary Dismissal with Prejudice Against HCW Biologics on June 26, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

HCW Biologics Says B&I Contractors Drops Florida Lien Crossclaims, Settles Dispute over USD 1.1 Million Lien

Reuters
·
Jul 01

HCW Biologics regains compliance with Nasdaq

TIPRANKS
·
Jun 30

HCW Biologics Executes 1-for-6 Reverse Stock Split

Reuters
·
Jun 30